Beyond Air Stock (NASDAQ:XAIR)
Previous Close
$0.46
52W Range
$0.30 - $2.36
50D Avg
$0.46
200D Avg
$0.82
Market Cap
$31.07M
Avg Vol (3M)
$754.86K
Beta
-0.18
Div Yield
-
XAIR Company Profile
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
XAIR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CTKB | Cytek Biosciences, Inc. |
| LUNG | Pulmonx Corporation |
| TELA | TELA Bio, Inc. |
| NPCE | NeuroPace, Inc. |
| KIDS | OrthoPediatrics Corp. |
| TMDX | TransMedics Group, Inc. |
| RCEL | AVITA Medical, Inc. |
| SGHT | Sight Sciences, Inc. |
| DCTH | Delcath Systems, Inc. |
| CLPT | ClearPoint Neuro, Inc. |
| NARI | Inari Medical, Inc. |
| CVRX | CVRx, Inc. |
| LUCD | Lucid Diagnostics Inc. |